Moreover, VRP-HER2 showed good tolerance in a phase I trial in stage IV HER2 overexpressing breast cancer patients and generated partial response (PR) in one patient and continued stable disease (SD) in two other patients [170]. Here, ERBB2 is linked to breast carcinoma.